Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer’s Disease Pathology  by Ulrich, Jason D. et al.
Neuron
PreviewsRe-evaluation of the Blood-Brain Barrier
in the Presence of Alzheimer’s Disease PathologyJason D. Ulrich,1,2,3 Tien-Phat Huynh,1,2,3 and David M. Holtzman1,2,3,*
1Department of Neurology
2Hope Center for Neurological Disorders
3The Knight Alzheimer’s Disease Research Center
Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA
*Correspondence: holtzman@neuro.wustl.edu
http://dx.doi.org/10.1016/j.neuron.2015.10.008
Blood-brain barrier disruption is believed to occur in Alzheimer’s disease, which could influence the bioavail-
ability of drugs within the brain. However, in this issue of Neuron, Bien-Ly et al. (2015) report no evidence of
widespread blood-brain barrier dysfunction.Alzheimer’s disease (AD) is themost com-
mon cause of dementia, affecting over 5
million individuals in the United States.
As the population ages, the impact of
AD is expected to become even more se-
vere, with the number of cases of AD ex-
pected to triple by 2050. Cross-sectional
and longitudinal studies indicate that the
pathological process of AD begins with
the deposition of amyloid-b (Ab) plaques
in the brain 10–20 years prior to the
onset of cognitive impairment (Jack and
Holtzman, 2013). Subsequent to the
appearance of Ab plaques is the progres-
sive appearance of tau-containing neuro-
fibrillary tangles in the neocortex along
with neuronal death and themanifestation
of clinical dementia (Jack and Holtzman,
2013). Currently there are no effective
treatments to cure, prevent, or slow the
progression of AD. Efforts at developing
a therapy for AD have largely focused
on reducing amyloid or tau pathology
through small molecule inhibitors of
Ab production or immunotherapy ap-
proaches targeting Ab or, more recently,
tau (Wisniewski and Gon˜i, 2015).
Drug development for diseases of the
central nervous system (CNS) has always
been particularly challenging due to the
restriction of the brain bioavailability of
therapeutics by the blood-brain barrier
(BBB), the specialized network of endo-
thelial cells, astrocytes, and pericytes
that restricts the entry of blood-borne
molecules into the CNS (Figure 1A) (Dane-
man and Prat, 2015). In the case of pas-
sive immunotherapy with monoclonal an-
tibodies, an intact BBB restricts all but
approximately 0.1%–0.2% of peripherallyadministered antibody from entering the
brain, meaning otherwise promising ther-
apy strategies may fail in the clinic
due to insufficient entry of the antibody
into the CNS with subsequent target
engagement (Figure 1B). One promising
approach to increase brain penetrance
of therapeutic antibodies is to engineer
them to be actively transported across
the BBB using an endogenous transcyto-
sis mechanism such as the transferrin re-
ceptor (TfR) (Watts and Dennis, 2013). For
example, previous studies found that bis-
pecific anti-BACE1/TfR antibodies ex-
hibited a pronounced increase in brain
uptake relative to anti-BACE1 antibodies
(Yu et al., 2014). However, to what degree
the BBB remains intact and an impedi-
ment to CNS drug delivery in the context
of neurodegenerative disease is unclear.
Neurovascular lesions are observed in
multiple sclerosis (MS) and AD patients,
and mouse models of neurodegenerative
diseases, such as the experimental
allergic encephalomyelitis (EAE) model
of MS, exhibit BBB breakdown (Zlokovic,
2011). On the one hand, the resulting
accumulation of neurotoxic peripheral
proteins and microbleeds could augment
neurodegeneration in AD; on the other
hand, a disrupted BBB could also allow
for greater brain bioavailability of thera-
peutics, which would obviate the need
for modification strategies to circumvent
the BBB.
In this edition of Neuron, Bien-Ly et al.
(2015) assessed whether there were
global disruptions in the BBB in mouse
models of AD that were sufficient to alter
the ability of antibodies to enter theNeuron 88CNS. The authors employed a variety of
neurodegenerative disease models and
a set of highly quantitative and sensitive
ELISAs and radiolabeled tracermethodol-
ogies to measure the degree of passive
diffusion through the BBB with a partic-
ular focus on the brain uptake of mono-
clonal antibodies. The authors elected to
compare the degree of passive antibody
diffusion in the context of various
neurodegenerative environments against
the bispecific anti-BACE1/TfR antibody,
which, as described previously, consis-
tently displayed greater brain uptake
than anti-BACE1 or a control IgG antibody
(Yu et al., 2014). In inflammatory condi-
tions known to cause massive disruption
of the BBB, such as the EAE model of
MS or following LPS injection, there was
a pronounced increase in the level of anti-
body and radiotracers detected in the
brain following peripheral administration
(Figure 1C). However, Bien-Ly et al.
(2015) found that there was no difference
between normal mice and mouse models
with AD pathology in regard to the levels
of antibody or radiotracers entering the
brain (Figure 1D). Consistent with these
findings, the levels of the plasma protein
albumin in the CNS were elevated in the
EAE mode, but not in the models
with AD pathology. Overall, the authors
conclude these results argue that the
BBB remains largely intact in the context
of Ab deposition or tauopathy, meaning
that strategies to increase CNS delivery
of AD therapeutics remains an important
area of study.
One significant contributor to BBB pa-
thology in AD is the presence of cerebral, October 21, 2015 ª2015 Elsevier Inc. 237
Figure 1. The Integrity of the BBB in Health and Disease
(A) Diagram of the neurovascular unit.
(B) A healthy BBB greatly restricts entry of plasma proteins such as IgGs into the brain.
(C) During inflammatory conditions such as EAE or LPS administration, there is a pronounced increase in BBB permeability correlating with breakdown of tight
junctions and a resulting increase in IgG penetrance into the brain.
(D) In the setting of AD pathology, the BBB remains largely intact and restricts the entry of plasma proteins, including IgG, into the brain.
(E) Amyloid deposition in the vasculature during CAA can weaken vessel integrity and damage the BBB, resulting in increased microhemorrhages, and may
influence the infiltration of IgG and many other proteins into the brain.
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ease that results from the deposition of
fibrillar Ab in cerebral arterial and capillary
vessel walls (Zlokovic, 2011). The pres-
ence of these vascular Ab deposits can
cause vascular smooth muscle dysfunc-
tion leading to reduced regional cerebral238 Neuron 88, October 21, 2015 ª2015 Elseblood flow and hemorrhaging. In addition
to CAA, though, previous studies have
suggested that soluble Ab species can
also affect vascular function and that
BBB dysfunction can precede plaque
deposition in mouse models (Biron et al.,
2011; Han et al., 2008). However, Bien-vier Inc.Ly et al. (2015) observed no evidence of
widespread BBB permeability in either
young PS2-APP mice with very little pla-
que deposition or in old PS2-APP mice
with more extensive plaque deposition.
As noted by Bien-Ly et al., PS2-APP
mice exhibit predominantly parenchymal
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Previewsrather than vascular fibrillar Abdeposition,
which may affect the degree to which Ab
pathology would influence BBB perme-
ability. Thus, it would be interesting to
apply the highly quantitative methods em-
ployed in this study to determine if the
presence of more extensive CAA affected
the passive diffusion of IgG into the brain
(Figure 1E).
In addition to assessing the integrity of
the BBB in neurodegenerative disease
models, Bien-Ly et al. (2015) also exam-
ined whether the presence of apoE4
altered BBB permeability to IgG. The
APOEε4 allele is the strongest known ge-
netic risk factor for developing late-onset
AD and also is associated with a greater
incidence of CAA. Furthermore, APOEε4
carriers have previously been reported to
exhibit changes in activity-dependent
regional cerebral blood flow without evi-
dence of AD pathology. Several studies
suggest that apoE4 is deleterious to
BBB function in vitro and in vivo. A previ-
ous study using demonstrated increased
BBB leakage using in vivo microscopy of
fluorescent tracers in young mice ex-
pressing apoE4 and in apoE/ mice
(Bell et al., 2012). The increased BBB
permeability observed in these mice
was associated with a decrease in apoE-
dependent pericyte-expressed LRP1
activation and a concomitant increase in
CypA-MMP9 activity (Bell et al., 2012). A
subsequent study found increased peri-
cyte degeneration and extravasation of
IgG in AD patients who were APOEε4
carriers compared to those who were
APOEε3 carriers (Halliday et al., 2015).
Interestingly, pericyte degeneration in
these subjects was correlated with
elevated levels of CypA and MMP9,
similar to what was observed in mice ex-
pressing apoE4 (Halliday et al., 2015).
However, Bien-Ly et al. observed no dif-
ference in apoE4 or apoE/ mice in the
level of brain IgG uptake or in the level of
radiotracer uptake in apoE/ mice. This
finding is in agreement with a recentreport that also found no difference in
the brain uptake of IgG or [14C]-sucrose
in mice expressing apoE2, E3, or E4
(Alata et al., 2015). The aggregate of
these results may suggest that, though
there may be highly localized apoE4-
dependent disruptions in BBB integrity,
these localized disruptions do not alter
the global homeostatic capacity of the
BBB.
Determining the brain bioavailability of
IgG used in passive immunotherapy for
AD is critically important, especially for
antibodies that target Ab or tau. Several
trials of Ab immunotherapies have re-
vealed a still poorly understood phenom-
enon observed in MRI scans known as
amyloid-related imaging abnormality
(ARIA) (Sperling et al., 2011). ARIA can
be associated with microhemorrhages or
vasogenic edema, possibly as a result of
an Ab clearance process or inflammation
(Sperling et al., 2011). Although the mech-
anistic basis for ARIA is unclear, the risk of
ARIA is increased in APOEε4 carriers and
is positively correlated with the presence
of CAA (Sperling et al., 2011). In addition,
higher dosing of Ab immunotherapy may
increase the risk of ARIA. Although Bien-
Ly et al. (2015) did not observe a change
in IgG brain bioavailability following a sin-
gle administration, it would be worthwhile
to test whether chronic dosing of an IgG,
particularly one targeting fibrillar Ab,
could alter the permeability of the BBB.
The allure of antibody therapy as a
‘‘magic bullet’’ for human disease con-
tinues to inspire passive immunotherapy
research. Given promising preclinical
data that passive immunotherapy against
Ab and tau alleviates neurodegenerative
phenotypes in mouse models, AD would
seem to be a target-rich environment.
The findings of a robust BBB presented
by Bien-Ly et al. (2015) would indicate
that methodologies to increase the
bioavailability of therapeutic antibodies
will continue to be an important facet of
AD immunotherapy efforts.Neuron 88ACKNOWLEDGMENTS
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